La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Editas Medicine Croissance future
Future contrôle des critères 2/6
Editas Medicine is forecast to grow earnings and revenue by 2.5% and 37.6% per annum respectively. EPS is expected to grow by 12.5% per annum. Return on equity is forecast to be -184.7% in 3 years.
Informations clés
2.5%
Taux de croissance des bénéfices
12.5%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 30.4% |
Taux de croissance des recettes | 37.6% |
Rendement futur des capitaux propres | -184.7% |
Couverture par les analystes | Good |
Dernière mise à jour | 09 Aug 2024 |
Mises à jour récentes de la croissance future
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 10Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
May 12Recent updates
Editas Medicine, Inc. (NASDAQ:EDIT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 10Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
May 12The Market Doesn't Like What It Sees From Editas Medicine, Inc.'s (NASDAQ:EDIT) Revenues Yet As Shares Tumble 25%
Apr 23Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Mar 09Editas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must Watch
Feb 28New Forecasts: Here's What Analysts Think The Future Holds For Editas Medicine, Inc. (NASDAQ:EDIT)
Dec 15Broker Revenue Forecasts For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
May 10Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Invest In Growth?
Jan 19Editas Medicine gains on report of potential sale of pre-clinical cancer pipeline
Oct 18Editas Medicine started at neutral at BofA due to competition in gene editing programs
Sep 29We're Hopeful That Editas Medicine (NASDAQ:EDIT) Will Use Its Cash Wisely
Sep 13Editas: End Of Year Data Readouts For SCD And Rare Eye Disease Studies
Aug 23Editas Medicine Q2 2022 Earnings Preview
Aug 02Baisong Mei joins Editas Medicine as Chief Medical Officer
Jul 18Is Editas Medicine (NASDAQ:EDIT) In A Good Position To Deliver On Growth Plans?
Jun 12Editas: Tackling Rare Eye Disease With Use Of Crispr Technology
Jun 06Editas: The Unforeseen Detrimental Effect Of Patent Win
Mar 25Editas: CRISPR Gene Editing Biotech With Promising Future
Mar 15Analysts' Revenue Estimates For Editas Medicine, Inc. (NASDAQ:EDIT) Are Surging Higher
Feb 25Editas Medicine: A Gene-Editing Company That Has Fallen Significantly In Price Recently
Dec 28Editas - The Introvert Crispr Biotech Too Shy To Flex Its Muscles
Dec 15Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Nov 17Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 48 | -276 | -324 | -254 | 12 |
12/31/2025 | 20 | -273 | -266 | -232 | 16 |
12/31/2024 | 24 | -247 | -179 | -171 | 17 |
6/30/2024 | 67 | -193 | -172 | -165 | N/A |
3/31/2024 | 69 | -166 | -151 | -146 | N/A |
12/31/2023 | 78 | -153 | -137 | -132 | N/A |
9/30/2023 | 25 | -195 | -156 | -152 | N/A |
6/30/2023 | 19 | -206 | -169 | -165 | N/A |
3/31/2023 | 23 | -219 | -168 | -164 | N/A |
12/31/2022 | 20 | -220 | -181 | -177 | N/A |
9/30/2022 | 26 | -201 | -176 | -170 | N/A |
6/30/2022 | 32 | -184 | -171 | -162 | N/A |
3/31/2022 | 26 | -186 | -174 | -164 | N/A |
12/31/2021 | 26 | -193 | -172 | -164 | N/A |
9/30/2021 | 24 | -214 | -176 | -169 | N/A |
6/30/2021 | 81 | -167 | -189 | -183 | N/A |
3/31/2021 | 92 | -135 | -180 | -175 | N/A |
12/31/2020 | 91 | -116 | -187 | -180 | N/A |
9/30/2020 | 92 | -91 | -106 | -99 | N/A |
6/30/2020 | 33 | -132 | -79 | -71 | N/A |
3/31/2020 | 24 | -142 | -73 | -66 | N/A |
12/31/2019 | 21 | -134 | -47 | -41 | N/A |
9/30/2019 | 14 | -121 | -86 | -80 | N/A |
6/30/2019 | 25 | -103 | -66 | -61 | N/A |
3/31/2019 | 30 | -108 | -57 | -52 | N/A |
12/31/2018 | 32 | -110 | -50 | -46 | N/A |
9/30/2018 | 29 | -121 | -76 | -72 | N/A |
6/30/2018 | 21 | -132 | -96 | -92 | N/A |
3/31/2018 | 17 | -120 | N/A | -102 | N/A |
12/31/2017 | 14 | -120 | N/A | -9 | N/A |
9/30/2017 | 11 | -124 | N/A | 2 | N/A |
6/30/2017 | 6 | -118 | N/A | 13 | N/A |
3/31/2017 | 6 | -111 | N/A | 29 | N/A |
12/31/2016 | 6 | -97 | N/A | -50 | N/A |
9/30/2016 | 6 | -71 | N/A | -45 | N/A |
6/30/2016 | 6 | -57 | N/A | -39 | N/A |
3/31/2016 | 2 | -86 | N/A | -9 | N/A |
12/31/2015 | 2 | -73 | N/A | -5 | N/A |
9/30/2015 | 1 | -66 | N/A | -1 | N/A |
6/30/2015 | 0 | -62 | N/A | 9 | N/A |
3/31/2015 | N/A | -17 | N/A | -13 | N/A |
12/31/2014 | N/A | -14 | N/A | -9 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: EDIT is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: EDIT is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: EDIT is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: EDIT's revenue (37.6% per year) is forecast to grow faster than the US market (8.8% per year).
Croissance élevée des revenus: EDIT's revenue (37.6% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: EDIT is forecast to be unprofitable in 3 years.